PDF(Pubmed)
Abstract：
Nanoengineering has emerged as a progressive method in cancer treatment, offering precise and targeted delivery of therapeutic agents while concurrently reducing overall toxicity. This scholarly article delves into the innovative strategies and advancements in nanoengineering that bridge the gap between clinical practice and research in the field of cancer treatment. Various nanoengineered platforms such as nanoparticles, liposomes, and dendrimers are scrutinized for their capacity to encapsulate drugs, augment drug efficacy, and enhance pharmacokinetics. Moreover, the article investigates research breakthroughs that drive the progression and enhancement of nanoengineered remedies, encompassing the identification of biomarkers, establishment of preclinical models, and advancement of biomaterials, all of which are imperative for translating laboratory findings into practical medical interventions. Furthermore, the integration of nanotechnology with imaging modalities, which amplify cancer detection, treatment monitoring, and response assessment, is thoroughly examined. Finally, the obstacles and prospective directions in nanoengineering, including regulatory challenges and issues related to scalability, are examined. This underscores the significance of fostering collaboration among various entities in order to efficiently translate nanoengineered interventions into enhanced cancer therapies and patient management.
摘要：
纳米工程已经成为癌症治疗的一种渐进方法，提供精确和靶向的治疗剂递送，同时降低整体毒性。这篇学术文章探讨了纳米工程的创新策略和进步，弥合了临床实践和癌症治疗领域研究之间的差距。各种纳米工程平台，如纳米颗粒，脂质体，和树枝状聚合物被仔细审查它们封装药物的能力，增强药物功效，并增强药代动力学。此外，这篇文章调查了推动纳米工程疗法进步和增强的研究突破，包括生物标志物的识别，建立临床前模型，和生物材料的进步，所有这些对于将实验室研究结果转化为实际的医疗干预措施都是必不可少的。此外，纳米技术与成像模式的整合，放大了癌症的检测，治疗监测,和反应评估，被彻底检查。最后,纳米工程的障碍和未来方向，包括与可扩展性相关的监管挑战和问题，被检查。这强调了促进各种实体之间合作的重要性，以便有效地将纳米工程干预措施转化为增强的癌症治疗和患者管理。
